Lack of association of B-type raf kinase V600E mutation with high-risk tumor features and adverse outcome in conventional and follicular variants of papillary thyroid carcinoma

Abstract

Introduction:Somatic B-type Raf kinase (BRAF) V600E mutation in exon 15 was frequently found in high frequencies associated with papillary thyroid cancer (PTC). The phenotype of these cancers expressed aggressive clinical and pathological features. The present study aimed to assess the prevalence of BRAF V600E mutation among conventional and follicular variants of PTC and its association with aggressive tumor factors and outcome.Study Design:Patients who were operated and received further treatment for PTC during 2012 were included in the study. BRAF V600E mutation analysis was done by extracting genomic DNA from tumor tissue.Results:Of the 59 patients included in the study, 51% harbored BRAF V600E mutation, but the mutation status was not associated with aggressive tumor factors and adverse outcome.Conclusion:BRAF V600E mutation was not significant predictor of aggressive tumor behavior in conventional and follicular variants of PTC.

Association of microRNA Expression and BRAFV600E Mutation with Recurrence of Thyroid Cancer

“…BRAF V600E usefulness as a prognostic marker in PTC remains controversial. Many previous studies reported a higher risk of PTC recurrence, metastases, and poor disease outcome in patients with BRAF V600E mutation, although there are plenty of studies that could not confirm any mutation-related associations [48][49][50]. These authors found that other factors, such as the presence of lymph node metastases, extrathyroidal invasion, or histologic type of PTC, provide higher accuracy in predicting disease outcome than BRAF mutation status alone [49][50][51].…”

Identification of distinct cytomorphologic features in the diagnosis of NIFTP at the time of preoperative FNA: Implications for patient management

“…Molecular testing has been increasingly applied to guide subsequent management for patients with an equivocal thyroid FNA diagnosis. Interestingly, although there are some conflicting data in the literature, BRAF V600E–positive tumors are generally reported as being associated with more aggressive clinical disease . A recent meta‐analysis by Liu et al showed that in addition to a higher TNM stage, lymph node metastases and the recurrence status correlate with the presence of a BRAF V600E mutation.…”

“…Interestingly, although there are some conflicting data in the literature, BRAF V600Epositive tumors are generally reported as being associated with more aggressive clinical disease. [19][20][21] A recent metaanalysis by Liu et al 20 showed that in addition to a higher TNM stage, lymph node metastases and the recurrence status correlate with the presence of a BRAF V600E mutation. Although we have limited follow-up data regarding our cohort of cases, we do note that although the T classification was not statistically different between the groups, lymph node metastases and BRAF positivity were detected more often in the invasive FVPTC cases versus the NIFTP cases.…”

Clinical, morphological, and prognostic features of papillary thyroid carcinoma with different BRAF mutational status assessed by immunohistochemistry

“…Данные литературы о прогностической значимости BRAF V600E весьма противоречивы. Ряд исследователей [16] подчеркивают связь мутаций BRAF V600E с агрессивным поведением опухолей и неблагоприятным прогнозом, другие [17,18] допускают возможную прогностическую роль BRAF V600E наряду с мутациями промотора гена, кодирующего теломеразную обратную транскриптазу (TERT), третьи [19] не находят связи статуса BRAF с особенностями клинического течения и прогнозом. Несомненно, данное исследование, выполненное на относительно небольшом количестве материала, требует проведения не только анализа влияния статуса BRAF на выбор объема хирургического вмешательства, но и на радиойодотерапию с учетом ее эффективности, суммарной активности и количества курсов, а также интенсивности и длительности супрессивной гормональной терапии.…”